O. O. Thomsen

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

S N Rasmussen, K. Lauritsen, V. Binder, 1989, The New England journal of medicine.

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

K. Bendtzen, M. Svenson, C. Steenholdt, 2011, Alimentary pharmacology & therapeutics.

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

K. Bendtzen, C. Steenholdt, J. Brynskov, 2012, Alimentary pharmacology & therapeutics.

A comparison of budesonide with prednisolone for active Crohn's disease.

D. Jewell, P. Rutgeerts, P. Rutgeerts, 1994, The New England journal of medicine.

Corticosteroids for maintenance of remission in Crohn's disease.

A. Griffiths, R. Modigliani, K. Ewe, 2003, The Cochrane database of systematic reviews.

Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease.

O. B. Schaffalitzky de Muckadell, K. Lauritsen, V. Binder, 1991, Scandinavian journal of gastroenterology.

What do gastroenterologists in Europe tell cancer patients?

H. Wulff, P. Singer, P. Singer, 1993, The Lancet.

Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo‐controlled study

S. Hanauer, I. Lawrance, W. Sandborn, 2011, Alimentary pharmacology & therapeutics.

Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease

J. Jahnsen, J. Dahlerup, T. Klausen, 2022, NEJM Evidence.